Triple Analysis: Pancreatic Cancer, Angiogenesis and Peptides

BioSeeker Group AB
January 7, 2013
3820 Pages - SKU: BIOS4940027
Malignant Melanoma: KOL Insight
10/17/2014 | published by: FirstWord
Introduction Malignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report with insights from 12 leading US and European KOLs offering their latest views on current and late-stage pipeline products, why and  |  read more...
USD 6,495
Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014
10/25/2014 | published by: Global Markets Direct
Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014’, provides an overview of the Hormone-Sensitive Prostate Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic  |  read more...
USD 2,000
Global Proton Therapy Market 2014-2018
10/15/2014 | published by: TechNavio - Infiniti Research Ltd.
Global Proton Therapy Market 2014-2018 About Proton Therapy Proton therapy is a type of particle therapy which is used to treat cancer patients by means of proton beams irradiation. The main advantage of proton therapy is that  |  read more...
USD 2,500
Papillary Thyroid Cancer - Pipeline Review, H2 2014
10/25/2014 | published by: Global Markets Direct
Papillary Thyroid Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Papillary Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Papillary Thyroid Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic  |  read more...
USD 2,000
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
9/22/2014 | published by: Global Markets Direct
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline. This report  |  read more...
USD 2,000
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
9/30/2014 | published by: GlobalData
Solar PV Power in Turkey, Market Outlook to 2025, Update 2014 - Capacity, Generation, Levelized Cost of Energy, Equipment Market, Regulations and Company Profiles Summary Solar PV Power in Turkey, Market Outlook to 2025, Update 2014 -  |  read more...
USD 3,495
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
9/30/2014 | published by: GlobalData
Solar PV Power in Australia, Market Outlook to 2025, Update 2014 - Capacity, Generation, Levelized Cost of Energy, Equipment Market, Regulations and Company Profiles Summary Solar PV Power in Australia, Market Outlook to 2025, Update 2014 -  |  read more...
USD 3,495
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
9/30/2014 | published by: GlobalData
Exxon Mobil Corporation, Company Intelligence Report Summary Exxon Mobil Corporation (ExxonMobil) is an integrated oil and gas company involved in the exploration, production, refining and transportation of crude oil and natural gas, and the manufacture of petroleum  |  read more...
USD 3,495
PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023
9/30/2014 | published by: GlobalData
Apache Corporation, Company Intelligence Report Summary Apache Corporation (Apache) is a Texas-based independent oil and gas company involved in the exploration, exploitation, development and production of onshore and offshore oil and natural gas properties in five countries:  |  read more...
USD 4,995
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023
9/30/2014 | published by: GlobalData
PharmaPoint: HER2-Positive Breast Cancer -5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on  |  read more...
USD 4,995
 

SELECT A LICENSE

    Electronic Access
Single User Fulfilled by Publisher
  USD 5,175  
    Electronic Access
Global Site License Fulfilled By Publisher
  USD 12,937.50  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!